Weekly Topotecan in Patients Treated for Metastatic Colorectal Cancer

Completed · Phase 2

Conditions studied: Colon Cancer

In brief

This non-randomized phase II study is designed to assess the response rate and toxicity of weekly topotecan as second-line treatment in patients with relapsed or refractory metastatic colorectal cancer.

Key facts

Study ID

NCT00193167

Run by

SCRI Development Innovations, LLC

People needed

40

Starts

2004-01-01

Expected to finish

2006-04-01

Last updated by the study team

2011-05-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• To be included in this study, you must meet the following criteria:
• Metastatic colorectal cancer
• One previous chemotherapy for metastatic disease
• Measurable or evaluable disease
• Able to perform activities of daily living with assistance
• Adequate bone marrow, liver, and kidney function
• All patients must give written informed consent prior to study entry.

You may not qualify if…

• You cannot participate in this study if any of the following apply to you:
• Brain or meningeal involvement
• Serious active infection or underlying medical conditions
• Other active neoplasms are ineligible
• Pregnant or lactating
• Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.

Where it is running

• Tennessee Oncology — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.